Dupixent achieved $3.7B in Q4 sales ... strengthens its competitive position. Tyler Van Buren, TD Cowen: Asked about the timing of the dividend initiation. CFO Chris Fenimore explained it reflects ...

The ADEPT trial met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg (n=53) every two weeks after an initial ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

After several months, inflammatory disease medication Dupixent has finally reclaimed its spot atop the rankings for over-the-counter (OTC) and Rx brand marketing on TV. The Regeneron and Sanofi brand, ...

For night five of Tyler's Chromakopia Tour, the 33-year-old gave LA an unforgettable experience. By Cat Johnson It’s incredible to think about the evolution of Tyler, The Creator’s music.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo ...

The sBLA is supported by data from a pivotal trial evaluating the efficacy and safety of Dupixent in 106 adults with moderate-to-severe BP. The primary endpoint was met, with five times more ...

Guns N’ Roses drummer Matt Sorum said that despite singing at a recent charity concert, Steven Tyler won’t be going on tour again. "It was a really big moment for him because he hurt himself ...

After performing most of his latest album, “Chromakopia,” just two months ago at his annual Camp Flog Gnaw Carnival, Tyler, the Creator could’ve easily copied and pasted his well-received ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for Dupixent to treat adults with bullous pemphigoid.

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent (dupilumab) in adults ...